The Therapeutic Plasma Exchange Market is expected to grow at an 5.5 % CAGR during the forecast period for 2023-2031.
Plasma exchange is a biological procedure that removes large-molecular-weight substances such as harmful antibodies from the plasma. In this procedure, a large portion of plasma containing abnormal matter and toxins are removed from the components of WBCs, RBCs, and platelets and then replaced with replacement fluid, like fresh frozen plasma (FFP) i.e., donor plasma or albumin. It is performed to treat several chronic diseases as the first-line or as second line of treatment therapy in neurological and non-neurological conditions.
Therapeutic plasma exchange (TPE) can rapidly decrease plasma viscosity. Thus, it can improve patient outcomes in critically ill patients with COVID-19 by reducing plasma viscosity and thereby enhancing blood flow.
Global Therapeutic plasma exchange market is expected to offer the lucrative growth in the near future due to the rising prevalence of chronic diseases and ongoing research and clinical trials to determine the efficacy of plasma exchange over other treatments. Also, the outbreak of a new viral disease, COVID – 19, is also creating a massive demand for therapeutic plasma exchange and thereby drive the global market.
Market Segmentation
The Global Therapeutic plasma exchange market is segmented on the basis of product & technologies, end-users, and region. Based on the base of product and technology, the market is divided into the product (consumables & devices) and technology (centrifugation & membrane separation). On the basis of indication, the market is divided into neurological disorders, hematology disorders, renal disorders, and metabolic disorders. On the basis of end-users, the market is divided into blood collection centres & blood component providers, hospitals & transfusion centres, and other end users. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. North America accounted for the largest share of the market in 2019, followed by Europe and Asia Pacific. On the other hand, the Asia Pacific is projected to have the highest growth rate during the forecast period.
Competitive Landscape
Some of The Key Players in The Therapeutic Plasma Exchange Market:
- Terumo Bct, Inc.
- Fresenius Se & Co. KGaA
- Haemonetics Corporation
- Baxter International Inc.
- Asahi Kasei Medical Co. Ltd.
- Braun Melsungen Ag
- Cerus Corporation
- Kaneka Corporation
- Kawasumi Laboratories, Inc.
- Nikkiso Co., Ltd.
- Miltenyi Biotec
- Other Prominent Players
The Therapeutic Plasma Exchange Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 5.5 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product & Technologies, By Indication, By End-Users |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Terumo BCT, Inc., Fresenius SE & Co. KGaA, Haemonetics Corporation, Asahi Kasei Medical Co. Ltd., B. Braun Melsungen AG, Baxter International Inc., Cerus Corporation, Kaneka Corporation, Kawasumi Laboratories, Inc., Nikkiso Co., Ltd., Miltenyi Biotec, Medica S.p.A., Medicap Clinic GmbH, and Others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
